CoChat

Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting

Open access
Smith, Rosamund C., Cramer, Martin S., Mitchell, Pamela J., Capen, Andrew, Huber, Lysiane, Wang, Rong, Myers, Laura, Jones, Bryan E., Eastwood, Brian J., Ballard, Darryl, Hanson, Jeff, Credille, Kelly M., Wroblewski, Victor J., Lin, Boris K., Heuer, Josef G. · 2015 · Molecular Cancer Therapeutics
Cited by 37

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Skeletal muscle wasting occurs in a great majority of cancer patients with advanced disease and is associated with a poor prognosis and decreased survival. Myostatin functions as a negative regulator of skeletal muscle mass and has recently become a therapeutic target for reducing the loss of skeletal muscle and strength associated with clinical myopathies. We generated neutralizing antibodies to myostatin to test their potential use as therapeutic agents to attenuate the skeletal muscle wasting due to cancer. We show that our neutralizing antimyostatin antibodies significantly increase body weight, skeletal muscle mass, and strength in non–tumor-bearing mice with a concomitant increase in mean myofiber area. The administration of these neutralizing antibodies in two preclinical models of cancer-induced muscle wasting (C26 colon adenocarcinoma and PC3 prostate carcinoma) resulted in a significant attenuation of the loss of muscle mass and strength with no effect on tumor growth. We also show that the skeletal muscle mass– and strength-preserving effect of the antibodies is not affected by the coadministration of gemcitabine, a common chemotherapeutic agent, in both non–tumor-bearing mice and mice bearing C26 tumors. In addition, we show that myostatin neutralization with these antibodies results in the preservation of skeletal muscle mass following reduced caloric intake, a common comorbidity associated with advanced cancer. Our findings support the use of neutralizing antimyostatin antibodies as potential therapeutics for cancer-induced muscle wasting. Mol Cancer Ther; 14(7); 1661–70. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0681

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 37

Metadata

Authors
Smith, R. C., Cramer, M. S., Mitchell, P. J., Capen, A., Huber, L., Wang, R., Myers, L., Jones, B. E., Eastwood, B. J., Ballard, D., Hanson, J., Credille, K. M., Wroblewski, V. J., Lin, B. K., & Heuer, J. G.
Venue
Molecular Cancer Therapeutics
Published
2015-07-01
Volume
14
Issue
7
Pages
1661-1670
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2157550266
Cited by
37
References
6
FWCI
1.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0681
The paper
Smith, R. C., Cramer, M. S., Mitchell, P. J., Capen, A., Huber, L., Wang, R., Myers, L., Jones, B. E., Eastwood, B. J., Ballard, D., Hanson, J., Credille, K. M., Wroblewski, V. J., Lin, B. K., & Heuer, J. G. (2015). Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.